Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.790
-0.180 (-4.53%)
At close: Jun 10, 2026, 4:00 PM EDT
3.780
-0.010 (-0.26%)
After-hours: Jun 10, 2026, 4:00 PM EDT
Inventiva Revenue
In the year 2025, Inventiva had annual revenue of 7.93M EUR, down -46.17%. Inventiva had revenue of 2.32M in the half year ending December 31, 2025, a decrease of -86.00%.
Revenue (ttm)
7.93M EUR
Revenue Growth
-46.17%
P/S Ratio
98.25
Revenue / Employee
102,935 EUR
Employees
77
Market Cap
779.95M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.93M | -6.80M | -46.17% |
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | -4.39M | -30.61% |
| Dec 31, 2016 | 14.35M | 5.69M | 65.66% |
| Dec 31, 2015 | 8.66M | 2.36M | 37.55% |
| Dec 31, 2014 | 6.30M | 1.20M | 23.46% |
| Dec 31, 2013 | 5.10M | 5.06M | 10,977.19% |
| Dec 31, 2012 | 46.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 204.89M |
| Arbutus Biopharma | 191.45M |
| Theravance Biopharma | 109.78M |
| MeiraGTx Holdings | 79.76M |
| Lexicon Pharmaceuticals | 69.64M |
| Janux Therapeutics | 13.73M |
| Odyssey Therapeutics | 2.98M |
IVA News
- 1 day ago - Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents - GlobeNewsWire
- 6 days ago - Inventiva Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 8 days ago - Inventia Resumes Trading Of Ordinary Shares On Euronext Paris - Nasdaq
- 8 days ago - Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris - GlobeNewsWire
- 8 days ago - Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout - GlobeNewsWire
- 8 days ago - Inventiva files automatic mixed securities shelf - TheFly
- 8 days ago - Inventia Temporarily Halts Euronext Paris Trading Ahead Of Financing Transaction - Nasdaq
- 8 days ago - Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris - GlobeNewsWire